Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)12,356.00
  • Today's Change28.00 / 0.23%
  • Shares traded1.22m
  • 1 Year change9.99%
  • Beta0.3443
Data delayed at least 20 minutes, as of Jun 28 2024 16:48 BST.
More ▼

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. It offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.

  • Revenue in GBP (TTM)37.67bn
  • Net income in GBP5.01bn
  • Incorporated1992
  • Employees89.90k
  • Location
    AstraZeneca PLCCambridge Biomedical CampusCAMBRIDGE CB2 0AAUnited KingdomGBR
  • Phone+44 20 7304 5000Fax+44 20 7604 8151
  • Websitehttps://www.astrazeneca.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AZN:LSE since
announced		Transaction
value
Fusion Pharmaceuticals IncAnnounced19 Mar 202419 Mar 2024Announced20.08%2.30bn
Amolyt Pharma SASAnnounced14 Mar 202414 Mar 2024Announced18.15%1.05bn
Gracell Biotechnologies IncDeal completed26 Dec 202326 Dec 2023Deal completed18.40%1.10bn
Icosavax IncDeal completed12 Dec 202312 Dec 2023Deal completed22.39%862.87m
Data delayed at least 20 minutes, as of Jun 28 2024 16:48 BST.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
McKesson Corp244.35bn2.37bn59.91bn45.00k59.91bn45.00k
Gilead Sciences, Inc.21.71bn382.79m67.60bn18.00k67.60bn18.00k
Sanofi SA39.57bn3.85bn96.43bn87.99k96.43bn87.99k
Roche Holding AG51.66bn10.12bn180.64bn103.61k180.64bn103.61k
AstraZeneca plc37.67bn5.01bn191.12bn89.90k191.12bn89.90k
AbbVie Inc43.03bn4.71bn239.55bn50.00k239.55bn50.00k
Novo Nordisk A/S27.75bn10.14bn386.21bn66.02k386.21bn66.02k
Eli Lilly And Co28.42bn4.85bn680.54bn43.00k680.54bn43.00k
Data as of Jun 28 2024. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

21.13%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Dec 202368.51m4.42%
Wellington Management Co. LLPas of 31 Dec 202365.12m4.20%
The Vanguard Group, Inc.as of 01 May 202456.03m3.61%
Norges Bank Investment Managementas of 01 May 202434.36m2.22%
BlackRock Fund Advisorsas of 01 May 202429.84m1.93%
Legal & General Investment Management Ltd.as of 01 May 202415.31m0.99%
SSgA Funds Management, Inc.as of 01 May 202415.22m0.98%
BlackRock Advisors LLCas of 01 May 202415.09m0.97%
Fidelity Management & Research Co. LLCas of 01 May 202414.73m0.95%
Invesco Asset Management Ltd.as of 01 May 202413.37m0.86%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.